HotSpot Therapeutics to Present Preclinical Data from Small Molecule IRF5 Program at FOCIS 2025

On June 18, 2025 HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of oral, small molecule allosteric therapies targeting Smart Allostery platform-identified regulatory sites on proteins referred to as "natural hotspots," reported it will present preclinical data from the Company’s interferon regulatory factor 5 (IRF5) program in an oral and poster presentation at the 25th Annual Meeting of the Federation of Clinical Immunology Societies (FOCIS 2025), taking place June 24-27, 2025, in Boston, MA (Press release, HotSpot Therapeutics, JUN 18, 2025, View Source [SID1234653992]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Presentation details are as follows:

Title: Targeting IRF5: Discovery and Preclinical Development of Selective Small Molecule Inhibitors
Session: Late-Breaking Abstracts
Session Date and Time: Wed., Jun. 25, 3:15-5:15 PM ET
Presentation Time: 4:00-4:15 PM ET
Location: Salons H-K, Boston Marriott Copley Place, Boston, MA